Nimbus Therapeutics Raises $210 Million for Small Molecule Drug Discovery

Boston-based Nimbus Therapeutics, a biotech firm, has announced that it has secured $210 million in venture capital funding. This investment will support the company's efforts to advance its portfolio of drugs targeting various disorders, including cancer.

09/09/2023, 11:32PM

Related Articles (6)

  • logo

    BioPharma Dive

    Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise

    The Boston biotech has sold two experimental drugs — a liver disease medicine and a TYK2 inhibitor — to Gilead and Takeda respectively.

  • logo

    Nimbus Therapeutics raises $210 million in fundraising round

    The Boston-based biotech will work on new ‘small molecule’ drugs to combat cancer and other ailments.